{"guideline_source":"Davis et al","recommendation_summary":"For adults with moderate to severe atopic dermatitis, we recommend the use of dupilumab, tralokinumab, upadacitinib, abrocitinib, and baricitinib. Conditional recommendations are made for the use of phototherapy, methotrexate, azathioprine, cyclosporine, and mycophenolate, while systemic corticosteroids are not recommended.","reference_section":"Conclusions"}
{"guideline_source":"2020 FOCUSED UPDATES TO THE Asthma Management Guidelines","recommendation_summary":"In individuals ages 4 years and older with asthma, the preferred Step 3 (low-dose ICS) and Step 4 (medium-dose ICS) therapy is single-inhaler ICS-formoterol both daily and as needed (SMART). This therapy has been shown to reduce exacerbations and is appropriate for those with a history of severe exacerbations. The maximum daily dose should not exceed 12 puffs for individuals ages 12 years and older and 8 puffs for ages 4-11 years.","reference_section":"Implementation Guidance"}
